Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 57, No 4 (2006)
Review paper
Submitted: 2013-02-15
Published online: 2006-07-07
View PDF (Polish) Download PDF file
Get Citation

BRAF initiating mutations in the papillary thyroid carcinoma

Dagmara Rusinek, Elżbieta Gubała
DOI: 10.5603/ep.25732
·
Endokrynol Pol 2006;57(4):438-444.

open access

Vol 57, No 4 (2006)
Review Article
Submitted: 2013-02-15
Published online: 2006-07-07

Abstract

Among genetic alterations most important for the initiation of papillary thyroid carcinoma (PTC) is mutation T1799A in the BRAF gene which is the most frequent event (54.5%) in this type of thyroid cancer. It is seen in all stages, from microcarcinoma through clinically overt disease to anaplastic cancer. It has been shown that BRAF mutation is correlated with PTC histotype. It is identified most frequently in classical PTC and in tall cell variant. Moreover, BRAF mutation is described more often in older patients, whereas in young patients RET/PTC rearrangements dominate. In PTC cases with BRAF mutation V600E the prognosis is poorer, with more cancer invasiveness, metastasis and recurrence. The presence of BRAF mutation is related to the specific gene expression signature, different than in cancer cases showing RET/PTC rearrangement or no known initiating mutation.

Abstract

Among genetic alterations most important for the initiation of papillary thyroid carcinoma (PTC) is mutation T1799A in the BRAF gene which is the most frequent event (54.5%) in this type of thyroid cancer. It is seen in all stages, from microcarcinoma through clinically overt disease to anaplastic cancer. It has been shown that BRAF mutation is correlated with PTC histotype. It is identified most frequently in classical PTC and in tall cell variant. Moreover, BRAF mutation is described more often in older patients, whereas in young patients RET/PTC rearrangements dominate. In PTC cases with BRAF mutation V600E the prognosis is poorer, with more cancer invasiveness, metastasis and recurrence. The presence of BRAF mutation is related to the specific gene expression signature, different than in cancer cases showing RET/PTC rearrangement or no known initiating mutation.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

papillary thyroid carcinoma; BRAF; initiating mutation

About this article
Title

BRAF initiating mutations in the papillary thyroid carcinoma

Journal

Endokrynologia Polska

Issue

Vol 57, No 4 (2006)

Article type

Review paper

Pages

438-444

Published online

2006-07-07

Page views

524

Article views/downloads

2037

DOI

10.5603/ep.25732

Bibliographic record

Endokrynol Pol 2006;57(4):438-444.

Keywords

papillary thyroid carcinoma
BRAF
initiating mutation

Authors

Dagmara Rusinek
Elżbieta Gubała

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl